More than half of evaluable patients who received eltrombopag and pulsed dexamethasone achieved the study’s primary end point.
Currently, splenomegaly is not included as a prognostic factor in major prognostic models of Philadelphia-negative myeloproliferative neoplasms.
Researchers assessed the efficacy of rivaroxaban in comparison with other standard anticoagulants in children with acute venous thromboembolism.
Morning or evening administration makes no difference on time outside target INR range
Researchers compared the incidence of venous thromboembolism between children with peripherally inserted central catheters and children with tunneled lines.
Anticoagulants, antiplatelets, and thrombolytics for the treatment and/or prophylaxis of venous and arterial thrombosis.
The FDA has granted Fast Track designation to bomedemstat (IMG-7289; Imago BioSciences) for the treatment of essential thrombocythemia, a myeloproliferative disorder characterized by high platelet counts.
Elderly patients with immune thrombotic thrombocytopenia purpura often have atypical presentation, which can delay diagnosis and treatment.
The FDA has granted Orphan Drug designation to avatrombopag for the potential treatment of chemotherapy-induced thrombocytopenia, a complication that may lead to chemotherapy dose delays and regimen changes.
Significantly higher odds seen for all four components of MetS, with largest risk increase for hyperlipidemia
Researchers reviewed the diagnosis and management of several pregnancy-specific causes of thrombocytopenia.
Of patients with ADAMTS13 deficiency, those who had type O blood underwent fewer therapeutic plasma exchange procedures compared with patients with type A or B blood.
Researchers evaluated the safety and efficacy of open-label caplacizumab in patients who experienced disease exacerbation during blinded treatment.
C-reactive protein and urine albumin/creatinine ratio were associated with increased risk of bleeding in patients with thrombocytopenia due to hematologic malignancy.
Adding aspirin to direct-acting oral anticoagulant therapy without a clear indication may increase bleeding risk without decreasing thrombotic risk.
Of patients receiving eltrombopag, 78.9% reached platelet count targets, compared with 61.1% of patients receiving intravenous immunoglobulin.
Most individual pharmacokinetic parameter values fell within the expected range irrespective of dosage, VTE outcome, and bleeding events.
Patients treated with rituximab experienced improved relapse-free survival at 1 and 3 years but not 5 years after treatment compared with patients receiving corticosteroids alone.
Researchers assessed clinical outcomes with apixaban, low-molecular-weight heparin, and warfarin to treat venous thromboembolism in patients with cancer.
Patients who were older than 65 years, female, or hospitalized in the northeastern United States experienced increased incidence of intracranial hemorrhage.
Vitamin K antagonist treatment was found to decrease splanchnic vein thrombosis recurrence in patients with myeloproliferative neoplasms.
Researchers found no significant difference in venous thromboembolism recurrence rates between patients with and without autoimmune disorders.
Risk for venous thromboembolism was increased more than 2-fold for men with and without hypogonadism who received testosterone therapy.
This 2019 guideline update includes a review of new data on anticoagulant use and risk stratification in venous thromboembolism.
A new study aims to address the conundrum of coagulation risk in patients hospitalized for hematologic malignancies.
At a median follow-up of 36 months, patients with acute thrombotic thrombocytopenic purpura displayed impaired quality of life compared with the general population.
The FDA has approved the supplemental Biologics License Application for Nplate (romiplostim; Amgen) to expand treatment to newly diagnosed adult patients with immune thrombocytopenia.
Authors find rivaroxaban not noninferior to vitamin K antagonists for secondary thromboprophylaxis
Current guidelines recommend 5 weeks of postoperative prophylactic anticoagulation, but a new study suggests the duration of this treatment ought to be extended.
A review and meta-analysis of 25 randomized controlled trials showed that single-agent treatment strategies were generally more effective than combination strategies.
Researchers found a low incidence of thrombotic events in patients receiving ibrutinib, though some patients still experienced bleeding.
Researchers found that most instances of venous thromboembolism occurred while patients were receiving prophylaxis.
Splenectomy is often administered as third- or fourth-line therapy, but earlier administration may mitigate treatment-related complications.
Stroke occurred in no patients with normal ADAMTS13 activity but did occur in 27.6% of patients with ADAMTS13 activity below 70%, the cutoff for normal activity.
Risk for late-occurring thromboembolism was elevated in patients who underwent allogeneic transplantation, and risk factors varied by transplantation type.
Results from a new real-world study evaluating rivaroxaban (Xarelto; Janssen), a factor Xa inhibitor, in morbidly obese patients were recently published in Thrombosis Research. The retrospective cohort study analyzed data from 2 US claims databases (Truven MarketScan Commercial Claims and Encounters database and MarketScan Medicare Supplemental database) to evaluate the clinical and health/economic outcomes of…
Researchers assessed the efficacy of a target international normalized ratio of 1.8 compared with the standard of 2.5 for thromboprophylaxis following arthroplasty.
Long-term oral anticoagulation with vitamin K antagonists is recommended for most patients with myeloproliferative neoplasms experiencing thrombosis.
A new risk stratification score for venous thromboembolism was developed and validated in a cohort of more than 4000 patients with multiple myeloma.
Common causes of extreme thrombocytosis differed in inpatient and outpatient settings, according to a review of 44,490 patient records.
Eltrombopag and romiplostim demonstrated superior response compared with rituximab for persistent adult immune thrombocytopenia.
Rates of recurrence and bleeding were similar between the 3 treatments assessed, but rivaroxaban demonstrated lower mortality rates.
The American Society of Clinical Oncology released updates to their guidelines for thromboprophylaxis in patients with cancer.
Reinitiation of oral anticoagulant therapy may be warranted for some patients with atrial fibrillation who have a high risk of bleeding.
Researchers assessed whether loss of von Willebrand factor high-molecular-weight multimers was predictive of morbidity in thrombotic thrombocytopenic purpura.
Researchers interviewed clinicians and patients to develop a conceptual model of congenital thrombotic thrombocytopenic purpura.
New studies in morbidly obese patients suggest that direct oral anticoagulants may be a safe and efficacious treatment option for thromboembolism and atrial fibrillation.
Patients with secondary Evans syndrome demonstrated increased mortality compared with all other cohorts.
Incidences of recurrent thromboembolism and major bleeding did not significantly differ between patients receiving DOACs and patients receiving warfarin.
Combining caplacizumab with therapeutic plasma exchange could decrease hospital stays and treatment costs in the long term.
A higher proportion of black patients and female patients with thrombotic thrombocytopenic purpura had coexisting connective tissue disorders.